据 Woofun AI 消息，赛默飞世尔科技公司(TMO.US)定于 10 月 21 日披露第三季度财报，华尔街顶级分析师在此前已上调盈利预期，市场焦点转向业绩兑现。这一调整反映了机构对该公司在科研仪器及诊断领域持续盈利能力的信心增强。
财务共识预期呈现稳健增长态势。总部位于马萨诸塞州沃尔瑟姆的赛默飞世尔科技(TMO.US)在纽约证券交易所上市，分析师预计其每股盈利将达 6.40 美元，较去年同期的 5.79 美元有所提升。营收方面，共识预期为 119.3 亿美元。
Woofun AI 整理数据显示，对比去年 111.2 亿美元的营收基数，这一增长轨迹显示出清晰的扩张逻辑。
业务协同效应成为近期市场关注点。10 月 6 日，量子生物制药有限公司(QNTM.US)宣布与赛默飞世尔科技(TMO.US)临床研究部门达成合作，共同推进用于治疗多发性硬化症的 Lucid-MS 药品二期临床试验。受多重因素影响，周一 TMO 股价下跌 1.5%，收于 679.38 美元，市场在消化合作消息的同时进行短期估值调整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.